Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations

EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib) develop acquired resistance, mediated by second-site EGFR T790M mutation in >50% cases. Preclinically, afatinib (irreversible ErbB family blocker) plus cetuximab (anti-EGFR monoclonal antibody) overcomes T790M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Janjigian, Yelena Y., Smit, Egbert F., Groen, Harry J.M., Horn, Leora, Gettinger, Scott, Camidge, D. Ross, Riely, Gregory J., Wang, Bushi, Fu, Yali, Chand, Vikram K, Miller, Vincent A., Pao, William
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4155006/
https://ncbi.nlm.nih.gov/pubmed/25074459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0326
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados